Additional milestone payment made from Valeant to EyeGate for EGP-437

EyeGate Pharmaceuticals has received an additional milestone payment from Valeant Pharmaceuticals for worldwide commercial and manufacturing rights to its EyeGate II delivery system and EGP-437 combination product for uveitis, according to an EyeGate press release.

A total of $32.5 million in payments is possible for development-based and commercial milestones under the license agreement between the two entities.

“Overall, we believe that 2017 could be a transformational year for EyeGate, as we remain on track to submit the NDA for potential FDA approval of EGP-437 in uveitis by the end of the year and are targeting significant milestones in our independent programs evaluating EGP-437 in other indications,” Stephen From, president and CEO of EyeGate, said in the release.

EyeGate Pharmaceuticals has received an additional milestone payment from Valeant Pharmaceuticals for worldwide commercial and manufacturing rights to its EyeGate II delivery system and EGP-437 combination product for uveitis, according to an EyeGate press release.

A total of $32.5 million in payments is possible for development-based and commercial milestones under the license agreement between the two entities.

“Overall, we believe that 2017 could be a transformational year for EyeGate, as we remain on track to submit the NDA for potential FDA approval of EGP-437 in uveitis by the end of the year and are targeting significant milestones in our independent programs evaluating EGP-437 in other indications,” Stephen From, president and CEO of EyeGate, said in the release.